DGAT2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for DGAT2 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
20 Direct drug records from Target & Disease MCP | 12 Development records in target context | 21 Disease associations captured | 26 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
Biology signal
DGAT2 is evaluated using the DGAT2 family evidence returned by Target & Disease MCP. The family sits in the final triglyceride synthesis pathway, complementary to DGAT1, and is relevant where hepatic lipid storage, obesity, and metabolic-disease biology intersect.
Validation evidence
MCP retrieval returned 20 drug records, 12 development records, and 21 disease associations on a roll-up basis. Clinical Trials MCP returned 26 trial records, including S-309309 Phase 1 pharmacokinetic and mass-balance studies plus a Phase 2 obesity study.
Competition and differentiation
DGAT2 is less clinically crowded than broad lipid targets, but translation requires solving tissue exposure and metabolic tolerability. Programs should be compared on liver selectivity, triglyceride effects, weight/metabolic endpoints, and safety monitoring.
IP and partnering view
IP diligence should focus on chemistry, hepatic targeting, obesity or MASH-related use claims, and whether the candidate can be separated from earlier DGAT liabilities. Platform partnerships may matter if delivery or tissue exposure is the differentiator.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 26 registered trial records connected to DGAT2. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Effect of itraconazole on the pharmacokinetics of S-309309 in healthy participants | Phase 1 | Completed |
| Safety and efficacy study of S-309309 in obese adults | Phase 2 | Completed |
| Mass balance study of [14C]S-309309 oral capsule in healthy adult male participants | Phase 1 | No longer recruiting |
R&D Strategy Recommendation
DGAT2 is a focused metabolic target with a moderate evidence base. Advance only where a program has a clear liver/metabolic rationale and a safety thesis that can withstand comparison with DGAT1 and broader lipid-modulating strategies.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
